Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica

Next Previous
X
Search
Trial Profile

An evaluation of the safety and tolerability of different doses of Recombinant Anti HER2 for injection (open study section) HL02 in Chinese healthy male subjects compared HL02 with Herceptin ? the pharmacokinetics, safety ,tolerability and immunogenicity, randomized, double-blind, Comparative study of pharmacokinetics clinica

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HL-02 (Primary) ; Trastuzumab
  • Indications Breast cancer; Male breast cancer
  • Focus Pharmacokinetics

    • Most Recent Events

    • 21 Aug 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top